Subsequent Therapies for Adults With Primary Immune Thrombocytopenia Offer Divergent Benefits
A network meta-analysis of twenty-two randomized trials found that subsequent pharmacological treatments for adults with primary immune thrombocytopenia produce outcome-specific ...


